Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’

Former President Bill Clinton warned that abrupt changes to HIV funding could disrupt treatment and prevention programs, arguing that countries need a carefully planned transition toward greater ownership. Clinton Warns of HIV Treatment Disruptions On Tuesday, in a post on X, Clinton said decades of efforts had focused on lowering the cost of HIV medicines while expanding access to prevention and treatment. "Country ownership is the goal. But a deadline isn’t a transition plan," he said. He argued that making HIV medicines cheaper would not be enough if patients could not access them. "Cheaper medicines mean nothing if they never reach people," Clinton said, warning against allowing treatment to be interrupted or prevention efforts to stop. "What kind of country are we if we knowingly allow treatment to be interrupted, prevention to stop, and people to be left to die?" He also warned against reversing years of progress for political reasons. "We should be building for the possibility of tomorrow," Clinton said. "Destroying decades of hard work to score political points carries a cost measured in human lives." "And no perceived, short-term political victory is worth that," he added. We’ve spent decades working to lower the price of HIV medicines and expand access to prevention and treatment. Country ownership is the goal. But a deadline isn't a transition plan. Cheaper medicines mean nothing if they never reach people. What kind of country are we if we…— Bill Clinton (@BillClinton) September 29, 2026 Read Also: Merck's New HIV Treatment Works As Well As Top Drug In Late Trials FDA Approved Gilead’s Bixlenvo Last month, the FDA approved Gilead Sciences Inc.’s (NASDAQ:GILD) Bixlenvo, a once-daily single-tablet HIV treatment for adults who maintained virologic suppression. The approval was based on Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, which showed the treatment maintained viral suppression at 48 weeks and was generally well tolerated. The trials also found improved treatment satisfaction among patients switching from complex regimens, while ARTISTRY-2 showed no significant overall impact on patient weight. Global Health Funding Concerns On Monday, Eli Lilly and Company (NYSE:LLY) launched the Lilly Change the Course Commitment, a global health initiative aimed at expanding access to diabetes and obesity treatments in low- and middle-income countries by 2040. The company said it would focus on clinical development, medicine registration and strengthening local health systems. Last year, Microsoft Corp. (NASDAQ:MSFT) co-founder Bill Gates warned that child deaths were rising for the first time in decades as global health funding declined. Modeling estimated that 4.8 million children under age 5 would die in 2025, up from 4.6 million in 2024, while Gates warned that reduced funding could reverse progress in preventing childhood deaths. Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Read Also: Charlie Munger Calls U.S. Health Care A 'Disgrace' And Says Singapore Does It Better At 20% of Cost — U.S. Power Players 'Fight Like Tigers' For Money Photo courtesy: Shutterstock